Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry

Drugs & Aging ◽  
2017 ◽  
Vol 34 (6) ◽  
pp. 467-477 ◽  
Author(s):  
Ho-Jun Jang ◽  
Sang-Don Park ◽  
Hyun Woo Park ◽  
Jon Suh ◽  
Pyung Chun Oh ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Elderly Patients ◽  
Antiplatelet Therapy ◽  
Primary Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
St Elevation Myocardial Infarction ◽  
Triple Antiplatelet Therapy ◽  
Percutaneous Coronary ◽  
St Elevation

Incidence of dual antiplatelet therapy interruption within 1 year after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction

2019 ◽  
Vol 96 (1131) ◽  
pp. 9-13
Author(s):  
Chor Cheung Tam ◽  
Jeffrey Lee ◽  
Ki Wan Chan ◽  
Cheung Chi Lam ◽  
Yiu Tung Wong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Antiplatelet Therapy ◽  
Primary Percutaneous Coronary Intervention ◽  
Dual Antiplatelet Therapy ◽  
Univariate Analysis ◽  
Coronary Intervention ◽  
St Elevation Myocardial Infarction ◽  
Percutaneous Coronary ◽  
St Elevation

BackgroundAfter primary percutaneous coronary intervention (PPCI) in patients with acute ST elevation myocardial infarction (STEMI), dual antiplatelet therapy (DAPT) is recommended to continue for 1 year. Occasionally, DAPT interruption may be required due to bleeding issues or unplanned surgical procedures.ObjectiveTo systematically evaluate the incidence of DAPT interruption within 1 year after PPCI.Methods and resultsThis was a single-centre, retrospective registry study. Consecutive patients with STEMI who underwent PPCI from 2013 to 2017 (N=538) were recruited into the analysis. The primary outcome was the incidence of interruption of DAPT within 1 year from the index PPCI. Secondary outcomes included incidence of bleeding in 1 year and prevalence of high bleeding risk (HBR) criteria at index presentation. Within 1 year, 17.1% (84/490) of post-PPCI survivors needed DAPT interruption and 7.1% (35/490) had major bleeding (Bleeding Academic Research Consortium type 3 or 5). At index presentation, HBR criteria were present in 36.1% (194/538) of patients. On univariate analysis, age, female gender, anaemia, anticoagulation, diabetes, hypertension and being a non-smoker were associated with DAPT interruption. On multivariate analysis, age was the only independent factor to predict DAPT interruption.ConclusionDAPT interruption was not uncommon after PPCI in patients with STEMI particularly in the elderly. This has implication on stent selection during PPCI, and further studies are required to investigate which type of stent may best suit our real-life patients with STEMI.

Sign in / Sign up

Export Citation Format

Share Document